PMID- 36605456
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2398-8835 (Electronic)
IS  - 2398-8835 (Linking)
VI  - 6
IP  - 1
DP  - 2023 Jan
TI  - The influence of LPL S447X variants and obesity on lipid profile, oxidative 
      stress, and the risk of T2DM: A case-control study.
PG  - e1031
LID - 10.1002/hsr2.1031 [doi]
LID - e1031
AB  - AIMS: The present study aimed to investigate the association between lipoprotein 
      lipase (LPL) S447X polymorphism and type 2 diabetes mellitus (T2DM), obesity, 
      lipid profile, and oxidative stress parameters in a population from the Kurdistan 
      region of Iraq. METHOD: We studied 250 adults (51% female and 49% male) aged 
      45-65 years in four groups, obese and normal body mass index (BMI) diabetic 
      patients versus healthy normal BMI and obese individuals as controls. Lipid 
      profile and oxidative stress parameters were analyzed by colorimetric assay. The 
      LPL S447X genotypes were detected by polymerase chain reaction (PCR)-restriction 
      fragment length polymorphism. RESULTS: We found that the obese diabetic group had 
      higher levels of triglycerides (TG), cholesterol, and low-density 
      lipoprotein-cholesterol, and lower level of high-density lipoprotein-cholesterol 
      than other groups. Obese diabetic patients had higher anthropometric indices than 
      nonobese diabetic patients, obese and normal BMI controls. The levels of TG and 
      total oxidative status (TOS) were significantly lower and higher, respectively, 
      in normal BMI controls than in obese controls. Obese diabetic patients had a 
      lower level of total antioxidant capacity than nondiabetic obese controls. The 
      level of TOS was lower in nondiabetic controls compared to the patient groups. 
      Obese diabetic patients had the highest TOS and malondialdehyde levels. The LPL 
      SX genotype was associated with decreased the risk of T2DM by 79% (odds ratio 
      [OR] = 0.21; 95% confidence interval [CI]: 0.05-0.81, p = 0.03). Also, the 
      presence of this genotype reduced the risk of obesity by 39% (OR = 0.61; 95% CI: 
      0.07-4.90, p = 0.6). In all individuals, the presence of the SX genotype was 
      associated with significantly lower levels of fasting blood sugar (FBS) and TOS. 
      CONCLUSION: We report the influence of obesity on lipid profile in diabetic and 
      nondiabetic individuals and the effect of LPL SX genotype on decreased risk of 
      T2DM and reduced levels of FBS and TOS.
CI  - (c) 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
FAU - Ahmed, Gulshan Omar
AU  - Ahmed GO
AD  - Department of Clinical Biochemistry Kermanshah University of Medical Sciences 
      Kermanshah Iran.
FAU - Rahimi, Zohreh
AU  - Rahimi Z
AUID- ORCID: 0000-0001-7589-3307
AD  - Department of Clinical Biochemistry Kermanshah University of Medical Sciences 
      Kermanshah Iran.
AD  - Medical Biology Research Center, Kermanshah University of Medical Sciences 
      Kermanshah Iran.
FAU - Kohsari, Maryam
AU  - Kohsari M
AUID- ORCID: 0000-0002-1817-9147
AD  - Department of Clinical Biochemistry Kermanshah University of Medical Sciences 
      Kermanshah Iran.
FAU - Shakiba, Ebrahim
AU  - Shakiba E
AD  - Department of Clinical Biochemistry Kermanshah University of Medical Sciences 
      Kermanshah Iran.
LA  - eng
PT  - Journal Article
DEP - 20230102
PL  - United States
TA  - Health Sci Rep
JT  - Health science reports
JID - 101728855
PMC - PMC9808153
OTO - NOTNLM
OT  - LPL variants
OT  - anthropometric parameters
OT  - lipid profile
OT  - obesity
OT  - oxidative stress parameters
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflicts of interest. Zohreh Rahimi is an Editorial Board 
      member of Health Science Reports. and a co-author of this article. To minimize 
      bias, they were excluded from all editorial decision-making related to the 
      acceptance of this article for publication.
EDAT- 2023/01/07 06:00
MHDA- 2023/01/07 06:01
PMCR- 2023/01/02
CRDT- 2023/01/06 02:35
PHST- 2022/09/27 00:00 [received]
PHST- 2022/12/04 00:00 [revised]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2023/01/06 02:35 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/07 06:01 [medline]
PHST- 2023/01/02 00:00 [pmc-release]
AID - HSR21031 [pii]
AID - 10.1002/hsr2.1031 [doi]
PST - epublish
SO  - Health Sci Rep. 2023 Jan 2;6(1):e1031. doi: 10.1002/hsr2.1031. eCollection 2023 
      Jan.